Quick Answer
vTv Therapeutics Inc. reported Total Revenue of $0.00 for the year ending 2025.
- vTv Therapeutics Inc. showed a decrease of -100.0% in Total Revenue from 2024 to 2025.
- This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $30.0 thousand | Q2 2017: $13.0 thousand | Q3 2017: $15.0 thousand | Q4 2017: $233.0 thousand | Q1 2018: $2.06 million | Q2 2018: $2.47 million | Q3 2018: $3.38 million | Q4 2018: $4.52 million | Q1 2019: $921.0 thousand | Q2 2019: $1.83 million | Q3 2019: $8.0 thousand | Q4 2019: $7.0 thousand | Q1 2020: $8.0 thousand | Q3 2020: $7.0 thousand | Q1 2021: $987.0 thousand | Q2 2021: $9.0 thousand | Q3 2021: $3.00 million | Q1 2022: $2.00 million | Q2 2022: $9.0 thousand | Q3 2022: $0.00 | Q1 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $0.00 | Q1 2024: $1.00 million | Q2 2024: $0.00 | Q3 2024: $0.00 | Q1 2025: $0.00 | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 10 years of available data (2016 to 2025), vTv Therapeutics Inc.'s Total Revenue has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $1.02 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $2.02 million | Fiscal year 2021: $4.01 million | Fiscal year 2020: $6.41 million | Fiscal year 2019: $2.76 million | Fiscal year 2018: $12.43 million | Fiscal year 2017: $291.0 thousand | Fiscal year 2016: $634.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: